The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCraven House Capital Regulatory News (CRV)

Share Price Information for Craven House Capital (CRV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.20
Bid: 0.15
Ask: 0.25
Change: 0.00 (0.00%)
Spread: 0.10 (66.667%)
Open: 0.20
High: 0.20
Low: 0.20
Prev. Close: 0.20
CRV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Investment

20 Aug 2013 09:33

RNS Number : 0760M
Craven House Capital PLC
20 August 2013
 



20 August 2013

 

Craven House Capital Plc

("Craven House" or the "Company")

 

Update on Investment

 

The Company is pleased to announce that one of its investee companies, Pressfit Holdings plc ("Pressfit"), intends to begin preparations for an introduction to the AIM market ("AIM"). The directors of Pressfit believe an introduction to AIM will help facilitate expansion and further Pressfit's aim of becoming a major international company specialising in the manufacture and distribution of stainless steel pressfittings. The proposal is being put to Pressfit's shareholders at an Extraordinary General Meeting on 30 August 2013.

 

Pressfit is an unquoted UK public limited company with Hong Kong and Chinese subsidiaries, which utilises proprietary technology to manufacture high-precision, thin walled stainless steel and carbon steel pipes and fittings used for plumbing and heating applications in the commercial, residential, industrial and agricultural sectors. Craven House currently holds 36.9% of the issued share capital of Pressfit, following investments in January and June 2012, together with a convertible loan over a further 3% of the issued share capital. Mark Pajak, Acting Chairman of Craven House, is also Non-Executive Chairman of Pressfit.

 

Pressfit recently announced a partnership agreement ("Partnership Agreement") with GXM (AMCOPRESS) GROUP CO., LIMITED ("AMCO"). The directors of both Pressfit and Craven House believe that the Partnership Agreement will benefit Pressfit as not only does AMCO operate in the same market as Pressfit, but it is also providing significant investment, management and a live sales and distribution channel. As part of the Partnership Agreement, two representatives from AMCO have been nominated to join the board as non-executive directors at Pressfit's Annual General Meeting ("AGM") on 30 August 2013.

 

Also as part of the Partnership Agreement, AMCO has agreed to invest £1,575,000 into Pressfit by way of a convertible loan note. If converted, AMCO would hold 45.1% of Pressfit's enlarged share capital, with Craven House's holding reduced to 20.3% of the enlarged share capital (or 21.6% if Craven House converts its own convertible loan note). The conversion price for AMCO's convertible loan is 6.16p (£0.0616), reflecting the value that the AMCO agreement brings to Pressfit with AMCO's decades of industry experience and existing order book.

 

Background on AMCO

 

AMCO is a group of associated companies engaged in the research, manufacturing and distribution of pressfittings targeting global markets ("AMCO Group"). It started with the establishment of AMCO Engineering (HK) in 1992 by Mr. Siu Wai Eric NG (newly proposed director). After two decades of growth, it now has several joint ventures and global partnerships promoting the wider use of metal pressfittings. The main associated companies are Hong Kong-based Amco Engineering (HK) Co. Ltd. (engineering and R&D) and Anpro Co. Ltd. (distribution of fittings); Singapore-based Anpro Pressfit Pte Ltd. (production of metal pressfittings); and China-based Dong Sheng Group (copper pressfitting production). AMCO Group provides a complete solution for metal pressfittings systems made from stainless steel, carbon steel, and copper.

 

The circular sent by Pressfit to its shareholders, which includes notice of the AGM and EGM is available on Pressfit's website at:

http://www.pressfitholdings.com/Pressfit%20AGM_EGM%20Notice%205Aug2013.pdf 

 

Mark Pajak, Acting Chairman of Craven House, commented, "We are pleased that Pressfit intends to seek a quotation on AIM, and that they have entered into the Partnership Agreement with AMCO. The proposed quotation on AIM would help demonstrate the value that has been created in Pressfit since our initial investment and move Craven House closer to an exit from its position in the Company,. 

 

The Partnership Agreement with AMCO not only brings in significant funding for Pressfit's expansion plans, but also an experienced partner who comes with industry expertise and international contacts which can subsequently be leveraged by Pressfit."

 

For further information please contact:

 

Craven House Capital Plc:

 

www.cravenhousecapital.com

 

 

Alexandra Eavis

Non Executive Director & Company Secretary

 

Tel: 07590 831 323

 

 

Daniel Stewart & Company Plc:

(Nominated Adviser & Broker)

 

Antony Legge/James Thomas

Tel: 020 7776 6550

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPMMPTMBJTMBJ
Date   Source Headline
28th Feb 20247:00 amRNSInterim Results
4th Jan 20247:00 amRNSResult of Annual General Meeting
29th Nov 20232:48 pmRNSAnnual Results for year ended 31 May 2023
28th Nov 20234:08 pmRNSInvestee Companies' Update
16th Nov 20239:07 amRNSInvestee Companies’ Update: Garimon and Honeydog
23rd Oct 20237:00 amRNSInvestee company update: Bio Vitos
17th Oct 20237:46 amRNSInvestee Companies’ Update: Garimon and Honeydog
29th Aug 20231:34 pmRNSInvestee company update: Bio Vitos
3rd Jul 20231:32 pmRNSInvestee company update: Bio Vitos
3rd Mar 20236:15 pmRNSPortfolio Update
27th Feb 20233:30 pmRNSInterim Results
8th Feb 20237:00 amRNSInvestee company update: Bio Vitos
27th Jan 202311:33 amRNSResult of Annual General Meeting
29th Nov 20227:00 amRNSAnnual Results for Year Ended 31 May 2022
15th Nov 20222:42 pmRNSInvestee company update: Garimon Ltd
23rd Feb 20223:01 pmRNSInterim Results
21st Jan 202212:45 pmRNSResult of AGM
23rd Dec 20213:59 pmRNSNotice of AGM
29th Nov 20216:29 pmRNSAnnual Results for year ended 31 May 2021
24th Nov 20212:55 pmRNSInvestee company update: OneBas.Com Ltd.
26th Oct 20217:00 amRNSInvestee company update: YRRO Ltd
16th Mar 20211:06 pmRNSTR-1: Notification of major holdings
18th Feb 20213:07 pmRNSInterim Results
11th Feb 202111:21 amRNSTR-1: Notification of major holdings
5th Feb 202110:44 amRNSStatement Regarding Share Price Movement
18th Jan 20212:49 pmRNSResult of Annual General Meeting
21st Dec 20207:00 amRNSNotice of General Meeting
9th Dec 20207:00 amRNSInvestee Company Update: YRRO Ltd
3rd Dec 202012:43 pmRNSAnnual Results for year ended 31 May 2020
9th Nov 20209:45 amRNSChange of Auditor
9th Oct 20203:14 pmRNSTrading Update, Change of Auditor & 2020 Results
18th Sep 202010:57 amRNSInvestee company update: Magazinos.com
22nd Jun 20201:01 pmRNSTR-1: Notification of major holdings
18th Jun 202011:06 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
3rd Jun 20201:27 pmRNSTR-1: Notification of major holdings
1st Jun 20202:05 pmRNSSecond Price Monitoring Extn
1st Jun 20202:00 pmRNSPrice Monitoring Extension
22nd May 20209:43 amRNSResult of General Meeting
5th May 202010:42 amRNSTR-1: Notification of major holdings
1st May 202010:58 amRNSPosting of Circular
1st Apr 20203:39 pmRNSCoronavirus and Business Update
23rd Mar 202012:19 pmRNSOn-line Platform Launched by Investee, Rosedog Ltd
20th Mar 20205:01 pmRNSNotification of major holdings
13th Mar 20207:00 amRNSSimultaneous exercise of five Option Agreements
27th Feb 202011:22 amRNSIssue of Equity and Directors' Dealing
27th Feb 20207:00 amRNSInterim Results
25th Feb 20209:16 amRNSNotification of major holdings
24th Feb 20207:00 amRNSCraven House signs 5 Non-binding Option Agreements
18th Feb 20202:54 pmRNSTR-1: Notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.